Brain aging and Parkinson’s disease: New therapeutic approaches using drug delivery systems
详细信息 查看全文
- 作者：C. Rodrí ; guez-Nogalesa ; E. Garbayoa ; b ; M.M. Carmona-Abellá ; nc ; M.R. Luquinb ; c ; M.J. Blanco-Prietoa ; b ; mjblanco@unav.es" class="auth_mail" title="E-mail the corresponding author ; maria.blanco@nanomedicinas.es" class="auth_mail" title="E-mail the corresponding author
- 关键词：PD ; Parkinson&rsquo ; s disease ; DAergic ; dopaminergic ; SNpc ; substantia nigra pars compacta ; DA ; dopamine ; LB ; lewy body ; α-syn ; alpha synuclein ; L-DOPA ; levodopa ; MAO ; monoamine oxidase ; CNS ; central nervous system ; DDS ; drug delivery systems ; MPs ; microparticles ; NPs ; nanoparticles ; SNCA ; synucleinalpha non A4 component of amyloid precursor ; PLK ; Polo like kinase ; LAMP ; lysosomal associated membrane receptor protein ; LRRK2 ; leucine-rich repeat kinase 2 ; MPTP ; 1-methyl-4-phenyl-1 ; 2 ; 3 ; 6-tetrahydr
- 刊名：Maturitas
- 出版年：2016
- 出版时间：February 2016
- 年：2016
- 卷：84
- 期：Complete
- 页码：25-31
- 全文大小：1039 K
文摘
- •
The etiology of Parkinson’s disease (PD) is unknown, aging being the strongest risk factor for brain degeneration.
- •
The most promising therapeutic targets and strategies to delay the loss of dopaminergic neurons observed both in PD and aging are reviewed.
- •
The latest types of drug delivery system (DDS)-based strategies for PD treatment are summarized.
- •
The ongoing challenges for the discovery of new targets and the opportunities for DDS-based therapies discussed.
- •
The emerging strategies summarized in the review show promise for better therapies for PD.